“A big, headline-grabbing company is not always your best bet, assuming you’re a shrewd investor seeking to maximize your profits,” advises the author of today’s article – and this may be especially true when it comes to biotech stocks. What two “size benefits” do smaller companies have – and why does the “size factor” work? CLICK HERE.
“I think this is the ground floor of a market that could be worth more than $29 billion by the end of the decade,” declares the author of today’s article of the “New Biotech” sector he discusses: psychedelics. For more on the potential profit opportunities associated with the “Shroom Boom” – especially in light of recent news regarding an important, successful FDA…
The pharmaceutical company featured in today’s article, known for its innovative drug pipeline, is a late-stage biotech focused on developing novel, oral, small-molecule drugs for rare and serious diseases. Having gained 153.8% over the past year and 60.1% year-to-date, is this a good biotech stock to own? For a look at the factors that could influence its performance in the near…
When it comes to what makes a good tech company – and the secret to investing in the right one – the author of today’s article declares the following: “There’s one rule that I follow when investing in tech, and it’s served me well over my entire career…” What is this rule – and the secret to investing in tech?…
“These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential,” says the author of today’s article of the five stocks he highlights, all of which are smaller-cap tech companies trading under the $10 level. For these five tech stocks, CLICK HERE.
“The best big pharma stocks offer growth potential thanks to strong pipelines, steady income with dependable dividends, and the opportunity to invest in a business that can make a huge positive impact in the lives of millions of people,” advises the author of today’s article, who proceeds to highlight three such pharma stocks that may be among the best picks…
A new approach is evolving for the treatment of cancer, which, as today’s article explains, involves “discovering pairs of genes whose combined activity is vital to cancer cells, allowing a joint attack to kill tumors in a strategy known as ‘synthetic lethality’”. For a look at two startups focused on finding cancer’s combined weaknesses – and with drug candidates entering…
Of the biotech industry, the author of today’s article notes that it “has seen its share of losses over the past couple of months but that provides us the perfect opportunity to pick up shares of stocks that could see substantial gains in the months ahead.” With that, he proceeds to highlight three undervalued biotech stocks poised to see their…
The prospect of tighter regulation of the sector (particularly when it comes to mergers and drug approvals) and drug-pricing reform, as well as rising interest rates, have created a “perfect storm” bearing down on biotech stocks. As a result, after seeing massive gains in 2020, biotech stocks have pulled back. Do biotech investors have reason to worry, or is biotech’s…
“The kinds of biotechs best for investors who aren’t huge risk-takers are those that generate solid revenue growth, are profitable (or soon will be), and have promising pipelines,” advises the author of today’s article, who proceeds to highlight three stocks that appear to match this profile to consider buying this month. For more, CLICK HERE.